Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
Joined January 2014
- Tweets 1,845
- Following 224
- Followers 8,623
- Likes 65
210 Photos and videos
Avacta is pleased to announce that it has raised gross proceeds of approximately £9 million from institutional investors and existing shareholders. avacta.com/oversubscribed-st… #AVCT
7
10
111
33,718
In this video presentation, Avacta CEO Christina Coughlin reviews the new faridoxorubicin program data. avacta.wistia.com/s/2hfpqeap… #AVCT
6
22
120
10,567
Avacta today released updated Phase 1a/1b and pharmacokinetics, safety, toxicity and preliminary efficacy data with faridoxorubicin at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. avacta.com/avacta-presents-u… #AVCT
3
22
168
24,156
Download a copy of the poster at avacta.com/investors/publica… #AVCT
5
40
2,980
Posting of Annual Report and Notice of AGM. avacta.com/posting-of-annual… #AVCT
1
4
55
3,167
Avacta today announces that Richard Hughes, one of Avacta’s non-executive Directors, will become non-executive Chairman of Avacta following the Annual General Meeting (AGM) on June 22, 2026. avacta.com/board-director-ch… #AVCT
5
17
174
20,813
Avacta today published its unaudited preliminary results for the 12 months ended December 31, 2025. polaris.brighterir.com/publi… #AVCT
2
95
5,525
We’re pleased to share the recordings from our Science Day. The presentations explore comparative analyses of pre|CISION® payload delivery with AVA6103 vs approved ADCs, alongside updated in vivo studies of the AVA6207 dual payload delivery system. avacta.com/2026-science-day-… #AVCT
32
194
18,968
Avacta will announce its unaudited preliminary results for the year ended December 31, 2025 on May 19, 2026. avacta.com/notice-of-prelimi… #AVCT
7
98
9,393
Avacta will today present two new developments at its Science Day 2026 event. Comparative analyses of AVA6103 compared with now two approved Antibody-Drug Conjugates (ADCs). Also, updated in vivo studies of the dual payload delivery program, AVA6207. avacta.com/avacta-presents-n… #AVCT
2
24
194
22,590
As Head and Neck Cancer Awareness Month draws to a close, we recognize the patients, families, and advocates whose courage and persistence drive progress in these complex diseases. #AVCT #HeadAndNeckCancerAwareness #SalivaryGlandCancer #HopeWithoutCompromise #Oncology #preCISION
2
17
160
9,562
Salivary gland cancer, a rare subset of head and neck cancers, remains an area of significant unmet need. Through our pre|CISION® platform, we are committed to advancing new options for these patients. To everyone whose advocacy makes this research possible, thank you. #AVCT
9
133
3,751
In this video presentation, the Avacta team discusses the second presentation from this week’s #AACR26 Annual Meeting, our dual payload technology. avacta.wistia.com/medias/xkt… #AVCT
3
23
148
31,013
Thank you to everyone who stopped by our posters and connected with our team. We’re heading home energized and more focused than ever on the road ahead.
Read more: avacta.com/avacta-data-at-aa… #AVCT
7
109
3,280